CUSTOM is the first completed prospective clinical trial that used genetic analysis alone to assign cancer treatment for patients with one of three different cancers. Findings suggest patients, and their physicians, are eager to jump into next-era cancer care -- analysis of an individual's tumor to find and target genetic mutations that drive the cancer.